Work

Partial albinism and immunodeficiency in patients with Hermansky‐Pudlak Type II: Introducing 2 novel mutations

Year: 2020
Type: article
Study design: Case Report
Abstract: Hermansky-Pudlak syndrome (HPS) (OMIM: #608233) is a rare genetic disorder firstly described in 1959 by Frantisek Hermansky and Paulus Pudlak.1 HPS, which has been classified into ten different subtypes based on causative genes,2 clinically varies from mild to severe. The common clinical manifestations of all HPS subtypes are oculocutaneous albinism, and platelets dysfunction leads to bleeding tendency and/or the other appearances such as granulomatous and pulmonary fibrosis.3 Hermansky-Pudlak syndrome type 2, inherited as an autosomal recessive disease, arises from mutations of the AP3B1. AP3B1, located on the long arm of chromosome 5 (5q14.1), encodes the β3A subunit of the AP-3 complex.4 To transport cargo molecules including enzymes from trans-Golgi network (TGN) towards lysosomes, direct and indirect intracellular pathways are available. In the direct pathway, AP-3 complex works as an adaptor protein and is crucial for forming vesicles and selecting cargo molecules.5 These vesicles carry cargos to lysosomal-related organelles such as melanosomes, dense bodies of platelets and cytotoxic granules of CD8+ T cells and natural killer (NK) cells.6 The biogenesis and contents of these intracellular organelles would affect CTL and NK cells cytotoxicity and accumulation CD63 protein on the plasma membrane in patients with defective AP-3 complex.7, 8 Therefore, the clinical and laboratory finding of HPS2 patients were manifested by albinism, bleeding problems, platelet and CTL dysfunction, neutropenia and immunodeficiency.9, 10 Here in, we aim to report the clinical and molecular features of two unrelated patients with HPS2 who referred to immunology, Asthma, and Allergy Research Institute (IAARI). The study was approved by the ethics committee of IAARI. Blood samples were obtained from the patient and their parents after taking an informed written consent. We found two novel mutations including 2 large deletions in exon 14 and exon 10-25 in the patients, respectively. Patient 1 was a 13-year-old girl from first-degree consanguineous parents referred to IAARI. She had history of recurrent fever from 1 year of age; on physical examination, she presented with partial albinism, nystagmus, easy-bruising and recurrent epistaxis. She admitted several times to the hospital due to chronic diarrhoea and frequent urinary tract infections. Also, she had neurodevelopmental delay. Laboratory evaluation demonstrated leukopenia and neutropenia. Microscopic evaluation of peripheral blood revealed hypochromic red blood cells (RBCs) with mild anisocytosis. Her bone marrow aspirate showed normal maturation of all hematopoietic lineages. The giant cytoplasmic granules associated with Chediak-Higashi syndrome were not observed in the patient, and her hair shaft under microscope showed hypopigmentation. Therefore, the possibility of HPS syndrome type 2 was considered in the patient based on their clinical and laboratory data. Genetic analysis of the AP3B1 (NM_003664) revealed a novel homozygous complete deletion of exon 14 in the patient (Figure 1). To assess AP3P1 expression in the patient 1, RNA was extracted from fresh PBMCs of the patient and their parents. After conducting RT-PCR, no expression of AP3B1 was shown in the patient (Figure 1). Patient 2 was a 10-year-old boy from non-consanguineous parents who was referred to IAARI for recurrent infections. He was born as the second child of the family with congenital hypothyroidism, and his 12-year-old sibling was healthy. On physical examination, partial albinism, nystagmus and splenomegaly and developmental delay were noticed. He had history of septicaemia, recurrent otitis media, gingivitis, gingival haemorrhage and recurrent aphthous stomatitis. At age 2, immunological studies disclosed leukopenia, neutropenia and mild thrombocytopenia. Serum immunoglobulin estimation showed elevated levels of IgG and IgA and normal IgM. Microscopic studies of bone marrow showed megakaryocyte of normal quantity and morphology. These patients had no respiratory complaints or evidence of fibrosing lung disease. No evidence in favour of Chediak-Higashi syndrome was found in this patient too. Exon-by-exon analysis of the patient 2 genomic DNA revealed a deletion of exon 10 up to 25. The results were confirmed by the lack of AP3B1 mRNA expression in the patient (Figure 1). Unfortunately, RNA samples of his parents were not available. Both patients have been receiving granulocyte colony-stimulating factor (G-CSF) and antibiotics for their neutropenia and recurrent infections, respectively. Up to now, ten subtypes of HPS have been described that only HPS types 2 and 10 are considered as primary immunodeficiencies and listed in the 'disease of immune dysregulation' group according to IUIS 2019 classification.2 To distinguish between these two subtypes, seizures, hearing loss and neurodevelopmental delay associated with HPS10 can be helpful.2 HPS2 is a well-studied rare disease whose typical clinical manifestations included recurrent infections, pulmonary fibrosis, increased bleeding and partial albinism. Recurrent infections observed in patients with HPS2 result from impaired cytotoxicity activity of T cells and NK cells, while the numbers of these cells are normal.11 However, decreased NK cells numbers were observed in patients of our study. A total of 28 different mutations have been reported in the AP3B1 so far.12 Missense/nonsense mutations are the most common types of mutation of the AP3B1 followed by deletions. In the current study, the clinical and laboratory signs of two unrelated HPS2 patients were reported who showed the complete deletion mutation of exon 14 (patient 1) and deletion of exon 10-25 (patient 2) leading to absence a part of N-terminal region and a huge part of AP3 complex, respectively (Figure 1). The AP-3 complex consists of four subunits including δ, β3A, µ3A and σ3. Of these subunits, β3A is a large subunit ubiquitously expressed in different cell types and its defects would decrease the stability of AP-3 complex,4 although Wenham et al hypothesized if a mutation were occurred in N-terminal region could have more severe effect on clinical phenotype due to the lack of the β3A subunit.9, 10 However, both patients in the current study presented mild clinical phenotype of the disease, and until the time of writing the manuscript, no accelerated phase of the disease was noticed. Due to these large deletions, we could not confirm whether these mutations are de novo or not, as heterozygous state could not be detectable by conventional PCR, and this is our limitation. However, it should be noted that as rare cases of patients with HPS2 have been reported so far, this study can provide more information to find out the effect and relative contribution of different mutations in the clinical phenotype and severity of the disease. We would like to thank patients and their family members for their contribution in this study. The financial support of this study was provided by IAARI and Tehran University of Medical Sciences. The authors declare that they have no conflicts of interest. More data are available upon request.
Language: English
Subfield: Immunology
Open Access status: bronze
OpenAlex ID: W3082326331
FWCI: 0.412
Cites: 12
Cited by: 9
Related to: 10